TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study in The Lancet Digital Health evaluated FAHR-Face, an AI model trained on more than 40 million facial photographs, for estimating facial age and predicting survival risk in cancer patients. The researchers found associations between older-appearing faces and poorer survival, but the results do not establish that a photograph can determine an individual’s prognosis or that the model is ready for clinical use.
Researchers have developed and tested an artificial intelligence model that uses facial photographs to estimate apparent age and assess survival risk among cancer patients, reporting associations between older-appearing faces and poorer outcomes. The study, published in The Lancet Digital Health, describes the model as a potential source of prognostic information, but says further validation is needed before it can be translated into clinical care.
The system, called FAHR-Face, was pretrained on more than 40 million consumer-grade digital facial photographs using a method that learns image patterns without requiring a health label for every photograph. Researchers then adapted it for two different tasks: estimating age from facial appearance and directly predicting survival risk in cancer patients. These are related but distinct outputs; the survival model does not simply convert an age estimate into a prognosis.
For age estimation, the researchers fine-tuned the model using 743,152 publicly available facial images. They tested it in two clinical cohorts: 38,183 patients treated at Harvard-affiliated radiotherapy centers in the United States, including a small proportion with benign conditions, and 4,892 cancer patients who received radiotherapy in the Netherlands. On public image datasets, the age model had a mean absolute error of 5.1 years, the average absolute difference between estimated and actual age.
The survival model was fine-tuned using photographs of 34,363 cancer patients. The researchers also evaluated it on a held-out group of 3,820 patients and another independent patient dataset. In survival analyses adjusted for clinical prognostic factors, patients whose estimated facial age was higher than their chronological age had poorer survival. The report also gives 90-day mortality of 21.3% for the group whose estimated facial age was more than 20 years above chronological age, compared with 6% in the comparison group. Those figures describe study groups, not an individual patient’s expected outcome.
Potential Clues Beyond Routine Measures
The study explores whether a photograph could provide a noninvasive, relatively low-cost signal associated with a patient’s health and prognosis. Facial appearance can reflect a range of influences, including aging, illness, lifestyle and environment. If future studies show that the model adds reliable information to established clinical assessments, it could help researchers examine risk in settings where detailed measurements are limited.
For now, the findings are an association, not proof that facial features cause differences in survival or that using the tool improves decisions or outcomes. A model’s performance in research datasets does not by itself show that it can guide treatment safely. The study’s importance lies in testing a new research approach—not in establishing a replacement for a clinician’s assessment or standard prognostic measures.
digital facial age estimation device
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From FaceAge to FAHR-Face
The researchers had previously developed FaceAge, a deep-learning system that estimates biological age from facial photographs. In earlier work, a higher facial-age estimate was associated with poorer survival among cancer patients. That model was developed in a cohort that was mostly White and aged 60 or older, limiting how confidently its results could be applied to other populations.
FAHR-Face uses a larger image-pretraining dataset and was assessed in patient groups from the United States and the Netherlands. The researchers also examined how factors such as lighting, makeup, facial pose and cosmetic surgery affected age estimates, and used saliency mapping to identify facial regions that contributed to predictions. The study’s authors say broad training may help the model learn general image patterns, but testing across clinical populations remains necessary.
“Facial photographs may provide noninvasive prognostic information, although they require validation before clinical translation.”
— The study authors, as described in the News-Medical report
Clinical Use Still Unproven
The reported results do not establish how well FAHR-Face would perform in every cancer type, age group, or demographic population. Although the researchers examined performance across demographic and cancer subgroups, the supplied report does not give detailed subgroup results or enough information to judge whether accuracy and risk estimates were consistent for each group.
It is also unclear whether the model’s predictions would add useful information beyond existing clinical factors, how they should be interpreted for a particular patient, or whether using them would change care. The reported survival associations cannot show that a facial photograph alone can forecast an individual outcome. Independent validation and clinical evaluation are needed before any such role could be established.
Further Validation Before Care
The immediate next step is further testing in independent patient populations, with attention to demographic representation, cancer type and the practical conditions under which photographs are taken. Researchers would also need to establish whether predictions are reproducible and provide information beyond existing prognostic assessments.
The study does not set out a clinical rollout timetable. Until additional evidence is available, FAHR-Face should be understood as a research model. Patients should not use a facial-age estimate or photograph to make medical decisions; prognosis and treatment questions should be discussed with a qualified health professional.
Key Questions
What is FAHR-Face?
FAHR-Face is an AI system developed to estimate age from facial appearance and to predict survival risk directly from photographs of cancer patients. The study evaluated these as separate tasks.
Does a photograph show how long a person with cancer will live?
No. The study found group-level associations between facial-age estimates and survival outcomes. It does not establish that a photograph can determine an individual patient’s prognosis.
How accurate was the age-estimation model?
On public image datasets, the model’s mean absolute error was 5.1 years. That measure describes age-estimation performance in those datasets; it is not a measure of survival prediction accuracy.
Can the model be used in cancer care now?
The study says further validation is required before clinical translation. The reported findings do not establish FAHR-Face as a tool for making treatment or prognostic decisions.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
